Abstract
To define the clinical utilizations, effectiveness, and challenges of immune checkpoint inhibitors (ICIs) in cancer treatments. A systematic review of the literatures regarding the efficacy of ICI therapy in the management of advanced melanoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) was performed. The effectiveness and safety profile of anti-PD-1 (Nivolumab, Pembrolizumab, and Cemiplimab /PD-L1 (Atezolizumab, Durvalumab, and Avelumab), anti-CTLA-4 (Ipilimumab) drugs were measured and evaluated in several clinical trials via treatment-related indicators (response rate, survival rate, progression-free survival, overall survival, median overall survival, and treatment-related adverse events). Considering the increasing use of ICI therapy in days to come due to its great potential, this review can be valuable in assisting professional students or even oncologists to have a general overview of the role of ICIs in cancer immunotherapeutic, particularly targets the advanced melanoma, NSCLC, and HCC.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
